The sample’s revenue fell by 0.3% from the previous quarter to $20,207.5 million. In addition, the trailing 12-month (TTM) trend in revenue shows that after a spike between FY21 and FY22 amid the post-pandemic boom, the revenue growth for each of the five companies has fallen below the levels seen five years ago, impacted by a slack in the demand for discretionary projects – long-term contracts which are transformational in nature – amid the rising focus of clients to achieve cost efficiency for existing processes.
Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25
Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected
January 30, 2025